BTTC Investigators Publish Paper in Journal of Neuro-Oncology

BTTC Investigators Publish Paper in Journal of Neuro-Oncology

The primary objective of this BTTC 08-01 study was to evaluate the effects and determine the overall survival rates in patients with newly diagnosed glioblastoma without MGMT promoter methylation when administering a combination of bevacizumab and erlotinib following the completion of radiation therapy with temozolomide. This is the first large trial exclusively completed by the BTTC. The study included 48 patients who participated up to one year.

The combination of erlotinib and bevacizumab is tolerable but did not meet our primary endpoint of increasing survival. While the trial did not meet its therapeutic objective, the outcome results were comparable to other trials in MGMT unmethylated patients and might be a treatment option for patients who cannot tolerate temozolomide. Importantly, more trials are needed to find better therapies for GBM patients with an unmethylated MGMT promoter.

To read the Journal of Neuro-Oncology Abstract, click here.